It's interesting that Sar.epta's 4yr collaboration with Wilton & Fletcher was announced on 1 October 2015 and then on 1 October 2019, PYC announces their partnership with Lions, their lead target is Retinitis Pigmentosa and Sue Fletcher becoming PYC's Chief of R&D.
What a coincidence.
https://investorrelations.sarepta.com/static-files/e3513d32-a2f4-43be-88d2-418a1fbc8b87
https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvTDYD5wm0yxaZsO56ke92GA%3D%3D
Ann: Drug Delivery Greater Than 100% More Effective In Animals, page-31
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.21 | $1.13 | $387.7K | 327.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |